Loading…
← CockpitCompetitor Analysis › 600267.SS Zhejiang Hisun Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Zhejiang Hisun Pharmaceutical Co., Ltd. Class A600267.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Major Chinese API and generic-drug manufacturer with a long-standing Pfizer joint venture and broad export APIs business.

Momentum leader 88
Mkt cap
$2.19B
US dollars, full cap
Free float
93%
of shares outstanding
$/day
$76.2M
20-day average traded
Fwd P/E
15.0×
forward earnings
ROIC−WACC
+9.4 pp
WACC 5.6%
Hurdle
-8 pp
Req g minus delivered
Next earnings
128 days
26 Mar 2027
Close · CNYCN¥12.67
1D-1.4%
1W-3.5%
1M-4.5%
3M-9.2%
6M+13.5%
YTD+28.1%
1Y+14.9%
ATR %4.0%
52w lowhigh15.5% off high

What Zhejiang Hisun Pharmaceutical does

Major Chinese API and generic-drug manufacturer with a long-standing Pfizer joint venture and broad export APIs business.

Sells fermentation-based ingredients and finished generics, with domestic hospital sales exposed to China's volume-based procurement, where winners of government tenders sell at much lower prices, and exports to overseas generics makers. A 2012 joint venture with Pfizer produces and markets generics in China.

Products and services

  • Active pharmaceutical ingredients (APIs)
  • Generic formulations
  • CDMO services

Customers

  • Global generic-drug makers (API buyers)
  • Hospitals/pharmacies

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • API manufacturing + generics + CDMO

What could go right

  • Global API/generic-drug demand growth

What could go wrong

  • API price competition
  • Regulatory (FDA) inspection risk

Moat: narrow (scale, regulatory licence). Large-scale, FDA/EU-audited API manufacturing plus a long Pfizer joint-venture relationship.

Headquarters: Taizhou, Zhejiang, China · Employees: 8,751

Named competitors

Zhejiang Hisun Pharmaceutical at a glance

Size Zhejiang Hisun Pharmaceutical (600267.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.19B, the 1093rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.67 on 18 Nov 2026.

Performance Over six months the shares gained 13.5%, against -4.9% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue fell 7.0% over the last twelve months (peer median +5.0%); the operating margin is 15.3% (peer median 11.1%).

Valuation It trades at 15.0× forward earnings against a peer median of 21.6× (4th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -8 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 9.4 points above its cost of capital (5.6% WACC).

Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026600267.SS 116Peer median 97
Six months, rebased to 100: Zhejiang Hisun Pharmaceutical against the median of its 20 peers (local-currency closes).

Zhejiang Hisun Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥9.15BCN¥10.5BCN¥10.3BCN¥10.3BCN¥12.0B
Revenue growth—+2%0%-14%—
Gross profitCN¥5.42BCN¥4.26BCN¥3.81BCN¥3.65BCN¥4.47B
EBITDAn/aCN¥2.08BCN¥1.84BCN¥1.34BCN¥2.00B
Net incomeCN¥1.23BCN¥541MCN¥601M-CN¥93.2MCN¥489M
Free cash flowCN¥1.09BCN¥1.67BCN¥1.96BCN¥1.28BCN¥1.55B
Capital expenditureCN¥503MCN¥376MCN¥238MCN¥240MCN¥531M
Total debtCN¥1.71BCN¥3.22BCN¥4.50BCN¥6.20BCN¥7.16B

Quarterly statements and history in the cockpit →

Zhejiang Hisun Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%600867APLLTD603858214450301080H02RGC688428PRGO000250600285NAMS603707603456001330043621623696PBH009420600267.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Hisun Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%25×50×75×600867APLLTD214450301080H02688428PRGO60345600133696PBH600267.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Hisun Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%600867APLLTD603858214450301080688428PRGO600267.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zhejiang Hisun Pharmaceutical is the large dot.

Zhejiang Hisun Pharmaceutical competitors and peer comparison

Head to head with its named competitors (600267.SS vs 600521.SS vs 000739.SZ vs 600216.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Zhejiang Hisun Pharmaceutical 600267.SS$2.19B+14%-7%15%15.0×-9.7%
Zhejiang Huahai Pharmaceutical 600521.SS$3.61B0%+10%12%20.1×6.4%
Apeloa Pharmaceutical 000739.SZ$3.37B+17%-16%10%22.9×4.7%
Zhejiang Medicine 600216.SS$1.51B-26%-6%7%11.5×-7.8%
North China Pharmaceutical 600812.SS$1.08B-12%-21%5%n/a1.0%
Cspc Pharma 1093.HK$12.0B+10%+25%28%9.1×-10.7%
Zhejiang NHU 002001.SZ$11.8B-22%+11%33%9.7×-8.3%

How Zhejiang Hisun Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Hisun Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600267.SSPeer medianRank in peer set
1-month return-4.5%-5.4%11th highest of 21
6-month return+13.5%-4.9%6th highest of 21
Distance from 52-week high-15.5%-29.6%5th highest of 21
Revenue growth (TTM)-7.0%+5.0%4th lowest of 20
Operating margin15.3%11.1%7th highest of 19
Forward P/E15.0×21.6×4th cheapest of 15
Growth the price implies (Req g, 7 yrs)-9.7%2.8%3rd least demanding of 15
Growth delivered (Del g)-1.5%+13.1%2nd lowest of 15
Hurdle (Req g minus delivered)-8.2 pp-0.1 pp6th least demanding of 15
ROIC minus cost of capital+9.4 pp-1.2 pp4th highest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zhejiang Hisun Pharmaceutical 600267.SSChina$2.19B+14%-7%15%15.0×-9.7%-1.5%
Tonghua Dongbao Pharmaceutical 600867.SSChina$2.19B-12%+18%n/a25.4×0.9%+0.3%
Alembic Pharmaceuticals APLLTD.NSIndia$2.20B+39%+20%12%25.0×26.7%+6.5%
Shandong Buchang Pharmaceuticals 603858.SSChina$2.25B-7%+4%10%n/a-2.5%-5.8%
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%15.4×-11.0%+37.6%
Acrobiosystems 301080.SZChina$2.31B+65%+29%17%55.2×41.3%+27.7%
Haw Par H02.SISingapore$2.08B-25%-13%30%11.9×3.2%+15.7%
Regencell Bioscience RGCUnited States$2.33B-83%n/an/an/an/an/a
InnoCare Pharma 688428.SSChina$2.07B-7%+135%35%85.7×-10.9%+344.2%
Perrigo PRGOUnited States$2.35B+52%-4%5%6.7×14.1%+0.8%
Sam Chun Dang Pharm 000250.KSSouth Korea$2.36B-66%+23%7%n/an/an/a
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%15.9×-4.7%+10.6%
NewAmsterdam Pharma NAMSUnited States$2.37B-45%-26%-900%n/an/an/a
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%25.9×5.1%+6.4%
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%16.9×1.7%+15.7%
HUTCHMED (China) 0013.HKHong Kong$2.38B+14%-9%-6%35.9×47.0%+19.3%
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%n/an/an/a
Keymed Biosciences 2162.HKHong Kong$2.39B+7%0%-73%18.2×n/an/a
InSilico Medicine Cayman TopCo 3696.HKHong Kong$2.40B-33%+153%-7%85.2×37.9%+22.9%
Prestige Consumer Healthcare PBHUnited States$2.40B+7%+5%25%10.6×2.3%+2.9%
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%n/an/an/a

Questions

Who are Zhejiang Hisun Pharmaceutical's main competitors?
Named competitors: Zhejiang Huahai Pharmaceutical (600521.SS), Apeloa Pharmaceutical (000739.SZ), Zhejiang Medicine (600216.SS), North China Pharmaceutical (600812.SS), CSPC Pharmaceutical Group (1093.HK), Zhejiang NHU (002001.SZ). The cockpit's measured peer set (industry) also includes Tonghua Dongbao Pharmaceutical (600867.SS), Alembic Pharmaceuticals (APLLTD.NS), Shandong Buchang Pharmaceuticals (603858.SS), PharmaResearch (214450.KS), Acrobiosystems (301080.SZ), Haw Par (H02.SI).
Is Zhejiang Hisun Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 15.0× against a peer median of 21.6×, 4th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -8 pp: the price already allows for a slowdown.
How has Zhejiang Hisun Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +13.5% against -4.9% for the median peer; over one year +14.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.